RxDoctor Payments Data

Adrian Rivera-Flores, MD

Family Medicine · Belleview, FLNPI 1861472706

Payments from drug & device makers

$3,624in general payments, 2019–2025

Across 206 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$504
  • Novo Nordisk$428
  • Pfizer$322
  • Lilly USA, LLC$290
  • Sanofi-aventis U.S. LLC$201
  • Exact Sciences$199
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$1003%
  • Speaking & faculty fees$722%
  • Food & beverage$3,45295%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,624 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$158,832
Medicare patients
285
Services billed
5,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate115$142,208
TradjentaLinagliptin61$64,439
EliquisApixaban50$56,627
OzempicSemaglutide35$52,643
XareltoRivaroxaban27$29,464
MounjaroTirzepatide23$24,732
Tresiba Flextouch U-100Insulin Degludec15$23,931
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$18,356
LinzessLinaclotide14$15,787
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$11,916
Omeprazole274$5,669
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$5,046
Rosuvastatin Calcium368$4,912
Levothyroxine Sodium467$4,314
Amlodipine Besylate657$3,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$41$142,208115 claims
Boehringer IngelheimTradjenta$195$64,43961 claims
PfizerEliquis$322$56,62750 claims
Novo NordiskOzempic$428$52,64335 claims
Johnson & JohnsonXarelto$143$29,46427 claims
Lilly USA, LLCMounjaro$290$24,73223 claims
AbbVieLinzess, Synthroid$504$17,76355 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Belleview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →